Augmentation of hematopoiesis by fibroblast-mediated interleukin-6 gene therapy in mice with chemotherapy

Journal of Interferon and Cytokine Research

Volumn 18, Issue 4, 1998, Pages 227-233

  Cao, Xuetao ^a   Cai, Rong ^a   Ju, Dian Wen ^a   Tao, Qun ^a   Yu, Yizhi ^a   Wang, Jianli ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; INTERLEUKIN 6; NEOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROTECTION; CELL STRAIN 3T3; COLONY FORMATION; COLONY FORMING UNIT GM; CONTROLLED STUDY; FEMALE; GENE THERAPY; HEMATOPOIESIS; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; MEGAKARYOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ANIMALIA; MURINAE;

EID: 0031900581     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.227     Document Type: Article

References (43)

1. KISHIMOTO, T. (1989). The biology of interleukin 6. Blood 74, 1-10.
2. VAN SNICK, J. (1990). Interleukin 6: an overview. Annu. Rev. Immunol. 8, 253-278.
3. ANDERSON, W.F. (1994). Gene therapy for cancer. Hum. Gene Ther. 5, 1-10.
4. BLANKENSTEIN, T., and QIN, Z. (1996). Cancer vaccine in gene therapy. Gene Ther. 3, 95-96.
5. PARDOLL, D.M. (1993). Cancer vaccines. Immunol. Today 14, 310-314.
6. PORGADOR, A., FELDMAN, M., and EISENBACH, L. (1994). Immunotherapy of tumor metastasis via gene therapy. Nat. Immun. 13, 113-130.
7. RAM, Z., CULVER, K.W., WALBRIDGE, S., BLAESE, R.M., and OLDFIELD, E.H. (1993). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88.
8. SELDEN, R.F., SKOSKIEWICZ, M.J., HOWIE, K.B., RUSSELL, P.S., and GOODMAN, H.M. (1987). Implantation of genetically engineered fibroblasts into mice: implications for gene therapy. Science 236, 714-718.
9. WANG, J., CAO, X., ZHANG, W., YE, T., and TANI, K. (1996). Treatment of leukemia with fibroblast-mediated interferon alpha gene therapy alone or in combination with doxorubicin. Leuk. Res. 20, 379-384.
10. CLICK, R.P., LICHTOR, T., KIM, T.S., HANGOVAN, S., and COHEN, E.P. (1995). Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery 36, 548-555.
11. ELDER, E.M., LOTZE, M.T., and WHITESIDE, T.L. (1996). Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Hum. Gene Ther. 7, 479-487.
12. LOTZE, M.T., and RUBIN, J.T. (1994). The therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum. Gene Ther. 5, 41-55.
13. SOBOL, R.E., and ROYSTON, I. (1995). Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): a phase I study. Hum. Gene Ther. 6, 195-204.
14. TAHARA, H., LOTZE, M.T., ROBBINS, P.D., STIRKUS, W.J., and ZITVOGEL, L. (1995). IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum. Gene Ther. 6, 1607-1624.
15. CAO, X., ZHANG, W., GU, S., TAO, Q., ZHOU, Z., ZHENG, L., and YE, T. (1994). Experimental study on the augmentation of host immune functions by fibroblast-mediated human interleukin-6 gene therapy. Chin. J. Immunol. 10, 8-11.
16. KARASUYAMA, H., and MELCHERS, F. (1988). Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4, or 5, using modified cDNA expression vectors. Eur. J. Immunol. 18, 97-104.
17. GALMICHE, M.C., VOGEL, C.A., DELALOYE, A.B., SCHMIDT, P.M., HEALY, F., MACH, J.P., and BUCHEGGER, F. (1996). Combined effects of interleukin 3 and interleukin 11 on hematopoiesis in irradiated mice. Exp. Hematol. 24, 1298-1306.
18. DRIZE, N., CHERTKOV, J., SAMOILINA, N., and ZANDER, A. (1996). Effects of cytokine treatment (granulocyte colony-stimulating factor and stem cell factor) on hematopoiesis and the circulating pool of hematopoietic stem cells in mice. Exp. Hematol. 24, 816-822.
19. NETA, R., DOUCHES, S., and OPPENHEIM, J.J. (1980). Interleukin 1 is a radioprotector. J. Immunol. 136, 2483-2485.
20. OPPENHEIM, J.J., NETA, R., TIBERGHIEN, P., GRESS, R., KENNY, J.J., and LONGO, D.L. (1989). Interleukin 1 enhances survival of lethally irradiated mice treated with allogeneic bone marrow cells. Blood 74, 2257-2263.
21. TIBERGHEIN, P., LAITHIER, V., MABED, M., RACADOT, E., REYNOLDS, C.W., ANGONIN, R., LOUMI, R., PAVY, J.J., CAHN, J.Y., and NOIR, A. (1993). Interleukin 1 administration before lethal irradiation and bone marrow transplantation: early transient increase of leukocyte, erythrocyte, and platelet recovery. Blood 81, 1933-1939.
22. SCHWEIGER, C., FARBER, L., FUCHSEL, G., HEINRICH, D., and MEINERZ, W. (1995-1996). Apparent Stimulation of thrombopoiesis with interleukin-3 (IL-3) in chemotherapy induced myelosuppression. Biofactors 5, 73-74.
23. TSUJI TAKAYAMA, K., HARASHIMA, A., TAHATA, H., IZUMI, N., NISHIDA, Y., NAMBA, M., OKUDA, Y., OHTA, T., and KURIMOTO, M. (1996). IFN-gamma in combination with IL-3 accelerates platelet recovery in mice with 5-fluorouracil-induced marrow aplasia. J. Interferon Cytokine Res. 16, 447-451.
24. PATCHEN, M.L., MACVITTIE, T.J., WILLIAMS, J.L., SCHWARTZ, G.N., and SOUZA, L.M. (1991). Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery from radiation-induced hematopoietic depression. Blood 77, 472-480.
25. CARRACIOLO, D., CLARK, C.S., and ROVERA, G. (1989). Human interleukin-6 supports granulocytic differentiation of hematopoietic progenitor cells and acts synergistically with GM-CSF. Blood 73, 666-670.
26. DU, X.X., KELLER, D., MAZE, R., and WILLIAMS, D.A. (1993). Comparative effects of in vivo treatment using interleukin 11 and stem cell factor on reconstruction in mice after bone marrow transplantation. Blood 82, 1016-1022.
27. DU, X.X., NEBEN, T., DOLDMAN, S., and WILLIAMS, D.A. (1993). Effects of recombinant human interleukin 11 on hematopoietic reconstruction in transplant mice: acceleration of recovery of peripheral blood neutrophils and platelets. Blood 81, 27-34.
28. NEBEN, T.Y., LOEBELENZ, J., HAYES, L., McCARTHY, K., STOUDEMIRE, J., SCHAUB, R., and GOLDMAN, S.J. (1993). Recombinant human interleukin 11 stimulates megakaryocytopoiesis and peripheral platelets in normal and splenectomized mice. Blood 81, 901-908.
29. FRASCA, D., PIOLI, C., GUIDI, F., PUCCI, S., ARBITRIO, M., LETER, G., and DORIA, G. (1996). IL-11 synergizes with IL-3 in promoting the recovery of the immune system after irradiation. Int. Immunol. 8, 1651-1657.
30. ZSEBO, K.M., SMITH, K.A., HARTLEY, C.A., GREENBLATT, M., COOKE, K., RICH, W., and McNIECE, I.K. (1992). Radioprotection of mice by recombinant rat stem cell factor. Proc. Natl. Acad. Sci. USA 89, 9464-9468.
31. NOTHDURFT, W., SELIG, C., FLIEDNER, T.M., HINTZOBERTREIS, P., KREJA, L., KRUMWIEH, D., KURRLE, R., SEILER, F.R., and WEINSHEIMER, W. (1992). Hematological effects of rhGM-CSF in dogs exposed total body irradiation with a dose of 2.4 Gy. Int. J. Radiat. Biol. 61, 519-531.
32. MACVITTIE, T.J., MONROY, R.L., PATCHEN, M.L., and SOUZA, L.M. (1990). Therapeutic use of recombinant human G-CSF (rhG-CSF) in a canine model of sublethal and lethal whole-body irradiation. Int. J. Radiat. Biol. 57, 723-736.
33. SHERIDAN, W.P., MORSTYN, G., WOLF, M., DODDS, A., LUSK, J., MAHER, D., LAYTON, J.E., GREEN, M.D., SOUZA, L., and FOX, R.M. (1989). Granulocyte colony-stimulating factor and neutrophil recovery after high dose chemotherapy and autologous bone marrow transplantation. Lancet 2, 891-895.
34. BRANDT, S.J., PETERS, W.P., ATWATER, S.K., KURTZBERG, J., BOROWITZ, M.J., JONES, R.B., SHPALL, E.J., BAST, R.C. J.R., GILBERT, C.J., and OETTE, D.H. (1988). Effects of recombinant human granulocyte-macrophages colony stimulating factor on hematopoietic reconstruction after high dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med. 318, 869-876.
35. ALBIN, N., DOUAY, L., FOUILLARD, L., LAPORTE, J.P., ISNARD, F., LESAGE, S., OZSAHIN, H., BARDINET, D., NAJMAN, A., and GORIN, N.C. (1994). In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies. Bone Marrow Transplant. 14, 253-259.
36. OHWADA, A., RAFII, S., MOORE, M.S.A., and CRYSTAL, R.G. (1996). In vivo adenovirus vector-mediated transfer of the human thrombopoietin cDNA maintains platelet levels during radiation-and chemotherapy-induced bone marrow suppression. Blood 88, 778-784.
37. WRIGHTON, N.C., FARRELL, F.X., CHANG, R., KASHYAP, A.K., BARBONE, F.P., MULCAHY, L.S., JOHNSON, D.L., BARRETT, R.W., JOLLIFFE, L.K., and DOWER, W.J. (1996). Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273, 458-464.
38. ISHIBASHI, T., KIMURA, H., UCHIDA, T., KARIYONE, S., FRIESE, P., and BURSTEIN, S.A. (1989). Human interleukin-6 is a direct promoter of maturation of megakaryocytes in vitro. Proc. Natl. Acad. Sci. USA 86, 5953-5957.
39. KERST, J.M., SLAPER-CORTENBACH, I.C., VAN DER SCHOOT, C.E., HOOIBRINK, B., VON DEM BORNE, A.E., and VAN OERS, R.H. (1993). Interleukin-6 is a survival factor for committed myeloid progenitor cells. Exp. Hematol. 21, 1550-1557.
40. VELDHUIS, G.J., WILLEMSE, P.H., MULDER, N.H., LIMBURG, P.C., and DE VRIES, E.G. (1996). Potential use of recombinant human interleukin 6 in clinical oncology. Leuk. Lymphoma 20, 373-379.
41. NEBBER, J., and ROSENBERG, S.A. (1993). Phase I studies of the pharmacokinetic, toxicities and biological effects of interleukin-6 in patients with refractory advanced malignancies. J. Immunother. 13, 74-78.
42. ECKERT, H.G., STOCKSCHLADER, M., JUST, U., HEGEWISCH-BECKER, S., GREZ, M., UHDE, A., ZANDER, A., OSTERTAG, W., and BAUM, C. (1996). High-dose multidrug resistance in primary, human hematopoietic progenitor cells transduced with optimized retroviral vectors. Blood 88, 3407-3415.
43. CHANG, P.L., CAPONE, J.P., and BROWN, G.M. (1990). Autologous fibroblast implantation. Feasibility and potential problems in gene replacement therapy. Mol. Biol. Med. 7, 461-470.